BioNTech reported third-quarter revenue of EUR 1.29 billion, a 15% year-on-year decline, driven by lower covid vaccine sales. Management raised its guidance to EUR 1.7 billion-EUR 1.9 billion, or 3% higher at the midpoint. Shares fell 1% from the previous day's close.
BioNTech owns a diverse portfolio of modalities for oncology, including bispecific antibodies, antibody-drug conjugates, and mRNA cancer vaccines, which gives it freedom to explore these in combination for possible synergies.
BioNTech's technology is still relatively new, with no oncology approvals to establish use in this setting.
Metric | BNTX | REGN | MRNA |
|---|---|---|---|
Price/Earnings (Normalized) | — | 17.76 | — |
Price/Book Value | 1.06 | 2.79 | 14.25 |
Price/Sales | 7.64 | 5.70 | 42.99 |
Price/Cash Flow | — | 16.48 | — |
Metric | BNTX | REGN | MRNA |
|---|---|---|---|
Quick Ratio | 8.43 | 2.72 | 2.08 |
Current Ratio | 8.55 | 3.35 | 2.29 |
Interest Coverage | — | 106.89 | −79.21 |
Metric | BNTX | REGN | MRNA |
|---|---|---|---|
Return on Assets (Normalized) | −3.31% | 14.40% | −23.82% |
Return on Equity (Normalized) | −3.78% | 18.83% | −33.79% |
Return on Invested Capital (Normalized) | −4.37% | 15.64% | −31.83% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|M?Qv^$q | LOCK|n#y$X | $138B | |||
| Moderna Inc MRNA | LOCK|!?!#%%r | LOCK|VF | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|!&dK^K | LOCK|rPKh% | $93B | |||
| argenx SE ADR ARGX | LOCK|$>!tx!b | LOCK|#w | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|Sw!XRW% | LOCK|Xl | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|fM%WfVLb | LOCK|>w&t! | $30B | |||
| Incyte Corp INCY | LOCK|M^#xLb | LOCK|>& | $24B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|$&%<kf | LOCK|yQ>@ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|$>&mr% | LOCK|QS? | $15B |
United States